PARD6A Antibody (G-9): sc-74479

PARD6A Antibody (G-9) is a mouse monoclonal IgG2b antibody that detects PARD6A in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PARD6A, also known as PAR6C, is a crucial component in establishing cellular polarity and asymmetric cell division, vital processes for multicellular organism development and function. This 345 amino acid polypeptide features a PDZ domain and a CRIB-like motif that facilitates interaction with GTP-bound Rac and Cdc42, as well as with atypical protein kinase C isoforms PKCι/λ and PKCΩ. These interactions are essential for forming a ternary complex that plays a significant role in developing tight junctions at epithelial cell-cell contacts, thereby maintaining epithelial layer integrity. Additionally, PARD6A is involved in polarizing mother cells prior to asymmetric cell division in organisms such as Caenorhabditis elegans. PARD6A expression is prominent in pancreas, skeletal muscle, brain, and heart, with lower levels detected in kidney and placenta, highlighting importance in various physiological contexts. PARD6A (G-9) antibody serves as an invaluable tool for researchers studying cellular polarity and implications in developmental biology and cancer research.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PARD6A Antibody (G-9) References:

1. Transforming growth factor-beta-stimulated endocardial cell transformation is dependent on Par6c regulation of RhoA.  |  Townsend, TA., et al. 2008. J Biol Chem. 283: 13834-41. PMID: 18343818
2. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity.  |  Hope, KJ., et al. 2010. Cell Stem Cell. 7: 101-13. PMID: 20621054
3. PAR6B is required for tight junction formation and activated PKCζ localization in breast cancer.  |  Cunliffe, HE., et al. 2012. Am J Cancer Res. 2: 478-91. PMID: 22957302
4. A genome-wide screen of CREB occupancy identifies the RhoA inhibitors Par6C and Rnd3 as regulators of BDNF-induced synaptogenesis.  |  Lesiak, A., et al. 2013. PLoS One. 8: e64658. PMID: 23762244
5. Alteration of tight junction gene expression in celiac disease.  |  Jauregi-Miguel, A., et al. 2014. J Pediatr Gastroenterol Nutr. 58: 762-7. PMID: 24552675
6. eNOS controls angiogenic sprouting and retinal neovascularization through the regulation of endothelial cell polarity.  |  Smith, TL., et al. 2021. Cell Mol Life Sci. 79: 37. PMID: 34971428
7. Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial-mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer.  |  Lu, Z., et al. 2022. Cell Death Dis. 13: 304. PMID: 35379775
8. Introduction of loxP sites by electroporation in the mouse genome; a simple approach for conditional allele generation in complex targeting loci.  |  Bernas, G., et al. 2022. BMC Biotechnol. 22: 14. PMID: 35549895
9. FOXN2, identified as a novel biomarker in serum, modulates the transforming growth factor-beta signaling pathway through its interaction with partitioning defective 6 homolog alpha, contributing to the pathogenesis of gastric cancer.  |  Li, L., et al. 2024. Growth Factors. 42: 62-73. PMID: 38954805
10. PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3.  |  Hu, L., et al. 2024. Cancer Gene Ther. 31: 1696-1707. PMID: 39300216

The preferred PARD6A antibody is PARD6A Antibody (C-3): sc-365323.